European Code against Cancer, 4th Edition: Cancer screening

Cancer Epidemiology

Volumn 39, Issue , 2015, Pages S139-S152

  Armaroli, Paola ^a   Villain, Patricia ^b   Suonio, Eero ^b   Almonte, Maribel ^b   Anttila, Ahti ^c   Atkin, Wendy S ^d   Dean, Peter B ^b   de Koning, Harry J ^e   Dillner, Lena ^f   Herrero, Rolando ^b   Kuipers, Ernst J ^e   Lansdorp Vogelaar, Iris ^e   Minozzi, Silvia ^a   Paci, Eugenio ^g   Regula, Jaroslaw ^h   Törnberg, Sven ⁱ   Segnan, Nereo ^a  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c FINNISH CANCER REGISTRY   (Finland)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g Cancer Prevention and Research Institute ISPO   (Italy)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ Regional Cancer Center Stockholm   (Sweden)

Author keywords

Breast neoplasms; Colorectal neoplasms; Europe; Mass screening; Prostatic neoplasms; Uterine cervical neoplasms

Indexed keywords

ADVANCED CANCER; ADVERSE OUTCOME; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CLINICAL EFFECTIVENESS; COLONOSCOPY; COLORECTAL CANCER; COLPOSCOPY; CYTOLOGY; EU CITIZEN; EUROPEAN CODE AGAINST CANCER 4TH EDITION; EUROPEAN UNION; EVIDENCE BASED PRACTICE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GROUPS BY AGE; HEALTH PROGRAM; HUMAN; INTESTINE CANCER; MAMMOGRAPHY; MASTECTOMY; META ANALYSIS (TOPIC); OCCULT BLOOD TEST; PAIN; PARTIAL MASTECTOMY; POPULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOLOGICAL ASPECT; RADIATION EXPOSURE; RISK ASSESSMENT; SCREENING TEST; SIDE EFFECT; SIGMOIDOSCOPY; SYSTEMATIC REVIEW; TASK PERFORMANCE; TIME TO TREATMENT; UTERINE CERVIX CANCER; WART VIRUS; EARLY CANCER DIAGNOSIS; FEMALE; MALE; NEOPLASMS; STANDARDS;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 84977444954     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2015.10.021     Document Type: Article

References (175)

1. [1] Boyle, P., Autier, P., Bartelink, H., Baselga, J., Boffetta, P., Burn, J., et al. European Code against Cancer and scientific justification: third version (2003). Ann. Oncol. 14 (2003), 973–1005.
2. [2] European Commission. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. Perry, N., Broeders, M., de Wolf, C., (eds.), 4th edition, 2006, Luxembourg: Office for Official Publications of the European Communities.
3. [3] Arbyn, M., Anttila, A., Jordan, J., Ronco, G., Schenck, U., Segnan, N., et al. European Guidelines for Quality Assurance on Cervical Cancer Screening. 2nd edition, 2008, European Community, Brussels; Office for Official Publications of the European Communities, Luxembourg.
4. [4] European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. Segnan, N., Patnick, J., von Karsa, L., (eds.), 1st edition, 2010, European Commission, Publications Office of the European Union, Luxembourg.
5. [5] Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2013, France: International Agency for Research on Cancer, Lyon accessed on day/month/year http://globocan.iarc.fr.
6. [6] von Karsa, L., Anttila, A., Ronco, G., Ponti, A., Malila, N., Arbyn, M., et al. Cancer screening in the European Union. Report on the Implementation of the Council Recommendation on cancer screening—First Report, 2008, European Communities, Luxembourg http://ec.europa.eu/health/ph_determinants/genetics/documents/cancer_screening.pdf.
7. [7] Minozzi, S., Armaroli, P., Espina, C., Villain, P., Wiseman, M., Schüz, J., et al. European Code against Cancer 4th Edition: process of reviewing the scientific evidence and revising the recommendations. Cancer Epidemiol 39 (2015), S11–S19.
8. [8] IARC, The European Code against Cancer. Available from: http://cancer-code-europe.iarc.fr.
9. [9] Hewitson, P., Glasziou, P., Irwig, L., Towler, B., Watson, E., Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst. Rev., 2007 CD001216.
10. [10] Zheng, S., Chen, K., Liu, X., Ma, X., Yu, H., Chen, K., et al. Cluster randomization trial of sequence mass screening for colorectal cancer. Dis. Colon Rectum 46 (2003), 51–58.
11. [11] Saito, H., Soma, Y., Koeda, J., Wada, T., Kawaguchi, H., Sobue, T., et al. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int. J. Cancer 61 (1995), 465–469.
12. [12] Saito, H., Soma, Y., Nakajima, M., Koeda, J., Kawaguchi, H., Kakizaki, R., et al. A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test. Oncol. Rep. 7 (2000), 815–819.
13. [13] Nakajima, M., Saito, H., Soma, Y., Sobue, T., Tanaka, M., Munakata, A., Prevention of advanced colorectal cancer by screening using the immunochemical faecal occult blood test: a case-control study. Br. J. Cancer 89 (2003), 23–28.
14. [14] Hol, L., Wilschut, J.A., van Ballegooijen, M., van Vuuren, A.J., van der Valk, H., Reijerink, J.C., et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br. J. Cancer 100 (2009), 1103–1110.
15. [15] Levi, Z., Birkenfeld, S., Vilkin, A., Bar-Chana, M., Lifshitz, I., Chared, M., et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate A prospective, controlled, feasibility study. Int. J. Cancer 128 (2011), 2415–2424.
16. [16] van Rossum, L.G., van Rijn, A.F., Laheij, R.J., van Oijen, M.G., Fockens, P., van Krieken, H.H., et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135 (2008), 82–90.
17. [17] Burch, J.A., Soares-Weiser, K., St John, D.J., Duffy, S., Smith, S., Kleijnen, J., et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J. Med. Screen. 14 (2007), 132–137.
18. [18] Whitlock, E.P., Lin, J.S., Liles, E., Beil, T.L., Fu, R., Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 149 (2008), 638–658.
19. [19] Federici, A., Giorgi Rossi, P., Borgia, P., Bartolozzi, F., Farchi, S., Gausticchi, G., The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J. Med. Screen. 12 (2005), 83–88.
20. [20] Hol, L., van Leerdam, M.E., van Ballegooijen, M., van Vuuren, A.J., van Dekken, H., Reijerink, J.C., et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59 (2010), 62–68.
21. [21] Hughes, K., Leggett, B., Del Mar, C., Croese, J., Fairley, S., Masson, J., et al. Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community. Aust. N. Z. J. Public Health 29 (2005), 358–364.
22. [22] Ko, C.W., Dominitz, J.A., Nguyen, T.D., Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am. J. Med. 115 (2003), 111–114.
23. [23] Hassan, C., Giorgi Rossi, P., Camilloni, L., Rex, D.K., Jimenez-Cendales, B., Ferroni, E., et al. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment. Pharmacol. Ther. 36 (2012), 929–940.
24. [24] Zhu, M.M., Xu, X.T., Nie, F., Tong, J.L., Xiao, S.D., Ran, Z.H., Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. J. Dig. Dis. 11 (2010), 148–160.
25. [25] Hoffman, R.M., Steel, S., Yee, E.F., Massie, L., Schrader, R.M., Murata, G.H., Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Prev. Med. 50 (2010), 297–299.
26. [26] Elmunzer, B.J., Hayward, R.A., Schoenfeld, P.S., Saini, S.D., Deshpande, A., Waljee, A.K., Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med., 9, 2012, e1001352.
27. [27] Thiis-Evensen, E., Hoff, G.S., Sauar, J., Langmark, F., Majak, B.M., Vatn, M.H., Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer: Telemark Polyp Study I. Scand. J. Gastroenterol. 34 (1999), 414–420.
28. [28] Hoff, G., Grotmol, T., Skovlund, E., Bretthauer, M., Norwegian colorectal cancer prevention study G. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ, 338, 2009, b1846.
29. [29] Atkin, W.S., Edwards, R., Kralj-Hans, I., Wooldrage, K., Hart, A.R., Northover, J.M., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375 (2010), 1624–1633.
30. [30] Segnan, N., Armaroli, P., Bonelli, L., Risio, M., Sciallero, S., Zappa, M., et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial—SCORE. J. Natl. Cancer Inst. 103 (2011), 1310–1322.
31. [31] Schoen, R.E., Pinsky, P.F., Weissfeld, J.L., Yokochi, L.A., Church, T., Laiyemo, A.O., et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N. Engl. J. Med. 366 (2012), 2345–2357.
32. [32] Baxter, N.N., Goldwasser, M.A., Paszat, L.F., Saskin, R., Urbach, D.R., Rabeneck, L., Association of colonoscopy and death from colorectal cancer. Ann. Intern. Med. 150 (2009), 1–8.
33. [33] Brenner, H., Haug, U., Arndt, V., Stegmaier, C., Altenhofen, L., Hoffmeister, M., Low risk of colorectal cancer and advanced adenomas more than 10 years after negative colonoscopy. Gastroenterology 138 (2010), 870–876.
34. [34] Brenner, H., Hoffmeister, M., Arndt, V., Stegmaier, C., Altenhofen, L., Haug, U., Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J. Natl. Cancer Inst. 102 (2010), 89–95.
35. [35] Brenner, H., Chang-Claude, J., Seiler, C.M., Rickert, A., Hoffmeister, M., Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann. Intern Med. 154 (2011), 22–30.
36. [36] Citarda, F., Tomaselli, G., Capocaccia, R., Barcherini, S., Crespi, M., Italian Multicentre Study G. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 48 (2001), 812–815.
37. [37] Kahi, C.J., Imperiale, T.F., Juliar, B.E., Rex, D.K., Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin. Gastroenterol. Hepatol. 7 (2009), 770–775 quiz 11.
38. [38] Lakoff, J., Paszat, L.F., Saskin, R., Rabeneck, L., Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study. Clin. Gastroenterol. Hepatol. 6 (2008), 1117–1121 quiz 064.
39. [39] Rabeneck, L., Paszat, L.F., Saskin, R., Stukel, T.A., Association between colonoscopy rates and colorectal cancer mortality. Am. J. Gastroenterol. 105 (2010), 1627–1632.
40. [40] Singh, H., Nugent, Z., Demers, A.A., Kliewer, E.V., Mahmud, S.M., Bernstein, C.N., The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology 139 (2010), 1128–1137.
41. [41] Singh, H., Nugent, Z., Mahmud, S.M., Demers, A.A., Bernstein, C.N., Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am. J. Gastroenterol. 105 (2010), 663–673 quiz 74.
42. [42] Zauber, A.G., Winawer, S.J., O'Brien, M.J., Lansdorp-Vogelaar, I., van Ballegooijen, M., Hankey, B.F., et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N. Engl. J. Med. 366 (2012), 687–696.
43. [43] Winawer, S.J., Zauber, A.G., Ho, M.N., O'Brien, M.J., Gottlieb, L.S., Sternberg, S.S., et al. Prevention of colorectal cancer by colonoscopic polypectomy: The National Polyp Study Workgroup. N. Engl. J. Med. 329 (1993), 1977–1981.
44. [44] Hardcastle, J.D., Chamberlain, J.O., Robinson, M.H., Moss, S.M., Amar, S.S., Balfour, T.W., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 (1996), 1472–1477.
45. [45] Kronborg, O., Fenger, C., Olsen, J., Jorgensen, O.D., Sondergaard, O., Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348 (1996), 1467–1471.
46. [46] Lindholm, E., Brevinge, H., Haglind, E., Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br. J. Surg. 95 (2008), 1029–1036.
47. [47] Mandel, J.S., Bond, J.H., Church, T.R., Snover, D.C., Bradley, G.M., Schuman, L.M., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood: Minnesota Colon Cancer Control study. N. Engl. J. Med. 328 (1993), 1365–1371.
48. [48] Scholefield, J.H., Moss, S., Sufi, F., Mangham, C.M., Hardcastle, J.D., Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 50 (2002), 840–844.
49. [49] Scholefield, J.H., Moss, S.M., Mangham, C.M., Whynes, D.K., Hardcastle, J.D., Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 61 (2012), 1036–1040.
50. [50] Mandel, J.S., Church, T.R., Ederer, F., Bond, J.H., Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J. Natl. Cancer Inst. 91 (1999), 434–437.
51. [51] van Roon, A.H., Goede, S.L., van Ballegooijen, M., van Vuuren, A.J., Looman, C.W., Biermann, K., et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 62 (2013), 409–415.
52. [52] Soares-Weiser, K., Burch, J., Duffy, S., St John, J., Smith, S., Westwood, M., et al. Diagnostic accuracy and cost-effectiveness of faecal occult blood tests (FOBT) used in screening for colorectal cancer: a systematic review. Database Abstr. Rev. Eff., 2, 2007, 221.
53. [53] Parker, M.A., Robinson, M.H., Scholefield, J.H., Hardcastle, J.D., Psychiatric morbidity and screening for colorectal cancer. J. Med. Screen. 9 (2002), 7–10.
54. [54] Lindholm, E., Berglund, B., Kewenter, J., Haglind, E., Worry associated with screening for colorectal carcinomas. Scand. J. Gastroenterol. 32 (1997), 238–245.
55. [55] Mant, D., Fitzpatrick, R., Hogg, A., Fuller, A., Farmer, A., Verne, J., et al. Experiences of patients with false positive results from colorectal cancer screening. Br. J. Gen. Pract. 40 (1990), 423–425.
56. [56] Atkin, W.S., Cook, C.F., Cuzick, J., Edwards, R., Northover, J.M., Wardle, J., et al. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 359 (2002), 1291–1300.
57. [57] Gondal, G., Grotmol, T., Hofstad, B., Bretthauer, M., Eide, T.J., Hoff, G., The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50–64 years. Scand. J. Gastroenterol. 38 (2003), 635–642.
58. [58] Segnan, N., Senore, C., Andreoni, B., Aste, H., Bonelli, L., Crosta, C., et al. Baseline findings of the Italian multicenter randomized controlled trial of once-only sigmoidoscopy–SCORE. J. Natl. Cancer Inst. 94 (2002), 1763–1772.
59. [59] Segnan, N., Senore, C., Andreoni, B., Arrigoni, A., Bisanti, L., Cardelli, A., et al. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J. Natl. Cancer Inst. 97 (2005), 347–357.
60. [60] Schoen, R.E., Pinsky, P.F., Weissfeld, J.L., Bresalier, R.S., Church, T., Prorok, P., et al. Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA 290 (2003), 41–48.
61. [61] Burke, C.A., Elder, K., Lopez, R., Screening for colorectal cancer with flexible sigmoidoscopy: is a 5-yr interval appropriate? A comparison of the detection of neoplasia 3 yr versus 5 yr after a normal examination. Am. J. Gastroenterol. 101 (2006), 1329–1332.
62. [62] Schoen, R.E., Pinsky, P.F., Weissfeld, J.L., Yokochi, L.A., Church, T., Laiyemo, A.O., et al. Colorectal cancers not detected by screening flexible sigmoidoscopy in the prostate, lung, colorectal, and ovarian cancer screening trial. Gastrointest. Endosc. 75 (2012), 612–620.
63. [63] Larsen, I.K., Grotmol, T., Bretthauer, M., Gondal, G., Huppertz-Hauss, G., Hofstad, B., et al. Continuous evaluation of patient satisfaction in endoscopy centres. Scand. J. Gastroenterol. 37 (2002), 850–855.
64. [64] Schoen, R.E., Weissfeld, J.L., Bowen, N.J., Switzer, G., Baum, A., Patient satisfaction with screening flexible sigmoidoscopy. Arch. Intern. Med. 160 (2000), 1790–1796.
65. [65] Ferlitsch, M., Reinhart, K., Pramhas, S., Wiener, C., Gal, O., Bannert, C., et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA 306 (2011), 1352–1358.
66. [66] Pox, C.P., Altenhofen, L., Brenner, H., Theilmeier, A., Von Stillfried, D., Schmiegel, W., Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 142 (2012), 1460–1467 e2.
67. [67] Regula, J., Rupinski, M., Kraszewska, E., Polkowski, M., Pachlewski, J., Orlowska, J., et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N. Engl. J. Med. 355 (2006), 1863–1872.
68. [68] Quintero, E., Castells, A., Bujanda, L., Cubiella, J., Salas, D., Lanas, A., et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N. Engl. J. Med. 366 (2012), 697–706.
69. [69] Graser, A., Stieber, P., Nagel, D., Schafer, C., Horst, D., Becker, C.R., et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 58 (2009), 241–248.
70. [70] Johnson, C.D., Fletcher, J.G., MacCarty, R.L., Mandrekar, J.N., Harmsen, W.S., Limburg, P.J., et al. Effect of slice thickness and primary 2D versus 3D virtual dissection on colorectal lesion detection at CT colonography in 452 asymptomatic adults. Am. J. Roentgenol. 189 (2007), 672–680.
71. [71] Johnson, C.D., Chen, M.H., Toledano, A.Y., Heiken, J.P., Dachman, A., Kuo, M.D., et al. Accuracy of CT colonography for detection of large adenomas and cancers. N. Engl. J. Med. 359 (2008), 1207–1217.
72. [72] Kim, Y.S., Kim, N., Kim, S.H., Park, M.J., Lim, S.H., Yim, J.Y., et al. The efficacy of intravenous contrast-enhanced 16-raw multidetector CT colonography for detecting patients with colorectal polyps in an asymptomatic population in Korea. J. Clin. Gastroenterol. 42 (2008), 791–798.
73. [73] Pickhardt, P.J., Choi, J.R., Hwang, I., Butler, J.A., Puckett, M.L., Hildebrandt, H.A., et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N. Engl. J. Med. 349 (2003), 2191–2200.
74. [74] Kaminski, M.F., Regula, J., Kraszewska, E., Polkowski, M., Wojciechowska, U., Didkowska, J., et al. Quality indicators for colonoscopy and the risk of interval cancer. N. Engl. J. Med. 362 (2010), 1795–1803.
75. [75] Bosworth, H.B., Rockey, D.C., Paulson, E.K., Niedzwiecki, D., Davis, W., Sanders, L.L., et al. Prospective comparison of patient experience with colon imaging tests. Am. J. Med. 119 (2006), 791–799.
76. [76] Condon, A., Graff, L., Elliot, L., Ilnyckyj, A., Acceptance of colonoscopy requires more than test tolerance. Can. J. Gastroenterol. 22 (2008), 41–47.
77. [77] Gluecker, T.M., Johnson, C.D., Harmsen, W.S., Offord, K.P., Harris, A.M., Wilson, L.A., et al. Colorectal cancer screening with CT colonography, colonoscopy, and double-contrast barium enema examination: prospective assessment of patient perceptions and preferences. Radiology 227 (2003), 378–384.
78. [78] Nicholson, F.B., Korman, M.G., Acceptance of flexible sigmoidoscopy and colonoscopy for screening and surveillance in colorectal cancer prevention. J. Med. Screen. 12 (2005), 89–95.
79. [79] Ristvedt, S.L., McFarland, E.G., Weinstock, L.B., Thyssen, E.P., Patient preferences for CT colonography, conventional colonoscopy, and bowel preparation. Am. J. Gastroenterol. 98 (2003), 578–585.
80. [80] van Gelder, R.E., Birnie, E., Florie, J., Schutter, M.P., Bartelsman, J.F., Snel, P., et al. CT colonography and colonoscopy: assessment of patient preference in a 5-week follow-up study. Radiology 233 (2004), 328–337.
81. [81] Multicentre Australian Colorectal-neoplasia Screening G, A comparison of colorectal neoplasia screening tests: a multicentre community-based study of the impact of consumer choice. Med. J. Aust. 184 (2006), 546–550.
82. [82] McLachlan, S.A., Clements, A., Austoker, J., Patients’ experiences and reported barriers to colonoscopy in the screening context—a systematic review of the literature. Patient Educ. Couns. 86 (2012), 137–146.
83. [83] Senore, C., Ederle, A., Fantin, A., Andreoni, B., Bisanti, L., Grazzini, G., et al. Acceptability and side-effects of colonoscopy and sigmoidoscopy in a screening setting. J. Med. Screen. 18 (2011), 128–134.
84. [84] Gotzsche, P.C., Jorgensen, K.J., Screening for breast cancer with mammography. Cochrane Database Syst Rev., 6, 2013, CD001877.
85. [85] Fitzpatrick-Lewis, D., Hodgson, N., Ciliska, D., Breast Cancer Screening. 2011, McMaster University, Hamilton, Ontario, Canada.
86. [86] Independent UKPoBCS, The benefits and harms of breast cancer screening: an independent review. Lancet 380 (2012), 1778–1786.
87. [87] Broeders, M., Moss, S., Nystrom, L., Njor, S., Jonsson, H., Paap, E., et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J. Med. Screen. 19:Suppl. 1 (2012), 14–25.
88. [88] Gabe, R., Duffy, S.W., Evaluation of service screening mammography in practice: the impact on breast cancer mortality. Ann. Oncol. 16:Suppl. 2 (2005), 53–62.
89. [89] Nelson, H.D., Tyne, K., Naik, A., Bougatsos, C., Chan, B.K., Humphrey, L., et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann. Intern. Med. 151:727–737 (2009), W237–W242.
90. [90] Moss, S.M., 16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. Lancet 353 (1999), 1909–1914.
91. [91] Tabar, L., Yen, M.F., Vitak, B., Chen, H.H., Smith, R.A., Duffy, S.W., Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361 (2003), 1405–1410.
92. [92] Peer, P.G., Werre, J.M., Mravunac, M., Hendriks, J.H., Holland, R., Verbeek, A.L., Effect on breast cancer mortality of biennial mammographic screening of women under age 50. Int. J. Cancer 60 (1995), 808–811.
93. [93] Jonsson, H., Tornberg, S., Nystrom, L., Lenner, P., Service screening with mammography in Sweden—evaluation of effects of screening on breast cancer mortality in age group 40–49 years. Acta Oncol. 39 (2000), 617–623.
94. [94] Hellquist, B.N., Duffy, S.W., Abdsaleh, S., Bjorneld, L., Bordas, P., Tabar, L., et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer 117 (2011), 714–722.
95. [95] Taylor, R., Page, A., Bampton, D., Estoesta, J., Rickard, M., Age-specific interval breast cancers in New South Wales and meta-analysis of studies of women aged 40–49 years. J. Med. Screen. 11 (2004), 199–206.
96. [96] Lynge, E., Olsen, A.H., Fracheboud, J., Patnick, J., Reporting of performance indicators of mammography screening in Europe. Eur. J. Cancer Prev. 12 (2003), 213–222.
97. [97] Hofvind, S., Ponti, A., Patnick, J., Ascunce, N., Njor, S., Broeders, M., et al. False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. J. Med. Screen. 19:Suppl. 1 (2012), 57–66.
98. [98] Puliti, D., Duffy, S.W., Miccinesi, G., de Koning, H., Lynge, E., Zappa, M., et al. Over-diagnosis in mammographic screening for breast cancer in Europe: a literature review. J. Med. Screen. 19:Suppl. 1 (2012), 42–56.
99. [99] Armstrong, K., Moye, E., Williams, S., Berlin, J.A., Reynolds, E.E., Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann. Intern. Med. 146 (2007), 516–526.
100. [100] Brett, J., Bankhead, C., Henderson, B., Watson, E., Austoker, J., The psychological impact of mammographic screening. A systematic review. Psycho-Oncol. 14 (2005), 917–938.
101. [101] Bond, M., Pavey, T., Welch, K., Cooper, C., Garside, R., Dean, S., et al. Systematic review of the psychological consequences of false-positive screening mammograms. Health Technol. Assess. 17 (2013), 1–170 v-vi.
102. [102] Brewer, N.T., Salz, T., Lillie, S.E., Systematic review: the long-term effects of false-positive mammograms. Ann. Intern. Med. 146 (2007), 502–510.
103. [103] Bijwaard, H., Brenner, A., Dekkers, F., van Dillen, T., Land, C.E., Boice, J.D. Jr, Breast cancer risk from different mammography screening practices. Radiat. Res. 174 (2010), 367–376.
104. [104] de Gelder, R., Draisma, G., Heijnsdijk, E.A., de Koning, H.J., Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths. Br. J. Cancer 104 (2011), 1214–1220.
105. [105] Hendrick, R.E., Radiation doses and cancer risks from breast imaging studies. Radiology 257 (2010), 246–253.
106. [106] Heyes, G.J., Mill, A.J., Charles, M.W., Mammography-oncogenecity at low doses. J. Radiol. Prot. 29 (2009), A123–32.
107. [107] O'Connor, M.K., Li, H., Rhodes, D.J., Hruska, C.B., Clancy, C.B., Vetter, R.J., Comparison of radiation exposure and associated radiation-induced cancer risks from mammography and molecular imaging of the breast. Med. Phys. 37 (2010), 6187–6198.
108. [108] Yaffe, M.J., Mainprize, J.G., Risk of radiation-induced breast cancer from mammographic screening. Radiology 258 (2011), 98–105.
109. [109] Barth, R.J. Jr., Gibson, G.R., Carney, P.A., Mott, L.A., Becher, R.D., Poplack, S.P., Detection of breast cancer on screening mammography allows patients to be treated with less-toxic therapy. Am. J. Roentgenol. 184 (2005), 324–329.
110. [110] Giorgi Rossi, P., Chini, F., Barca, A., Baiocchi, D., Federici, A., Farchi, S., et al. Efficacy of disease management profiles: the mammographic screening program of Lazio. Tumori 94 (2008), 297–303.
111. [111] Hofvind, S., Lee, C.I., Elmore, J.G., Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening program. Breast Cancer Res. Treat. 135 (2012), 291–299.
112. [112] Hofvind, S., Skaane, P., Stage distribution of breast cancer diagnosed before and after implementation of population-based mammographic screening. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 184 (2012), 437–442.
113. [113] Kaplan, H.G., Malmgren, J.A., Disease-specific survival in patient-detected breast cancer. Clinical Breast Cancer 7 (2006), 133–140.
114. [114] Malmgren, J.A., Parikh, J., Atwood, M.K., Kaplan, H.G., Impact of mammography detection on the course of breast cancer in women aged 40–49 years. Radiology 262 (2012), 797–806.
115. [115] Perez-Fidalgo, J.A., Miranda, J., Chirivella, I., Ibanez, J., Bermejo, B., Pons, C., et al. Impact of a mammography screening programme on the breast cancer population of the Region of Valencia (Spain). Clin. Transl. Oncol. 10 (2008), 745–752.
116. [116] Samnakay, N., Tinning, J., Ives, A., Willsher, P., Archer, S., Wylie, E., et al. Rates for mastectomy are lower in women attending a breast-screening programme. ANZ J. Surg. 75 (2005), 936–939.
117. [117] Spillane, A.J., Kennedy, C.W., Gillett, D.J., Carmalt, H.L., Janu, N.C., Rickard, M.T., et al. Screen-detected breast cancer compared to symptomatic presentation: an analysis of surgical treatment and end-points of effective mammographic screening. ANZ J. Surg. 71 (2001), 398–402.
118. [118] Walsh, P.M., McCarron, P., Middleton, R.J., Comber, H., Gavin, A.T., Murray, L., Influence of mammographic screening on trends in breast-conserving surgery in Ireland. Eur. J. Cancer Prev. 15 (2006), 138–148.
119. [119] Zorzi, M., Puliti, D., Vettorazzi, M., De Lisi, V., Falcini, F., Federico, M., et al. Mastectomy rates are decreasing in the era of service screening: a population-based study in Italy (1997–2001). Br. J. Cancer 95 (2006), 1265–1268.
120. [120] Crawford, M.D., Biankin, A.V., Rickard, M.T., Coleman, M.J., West, R., Niesche, F.W., et al. The operative management of screen-detected breast cancers. Aust. N. Z. J. Surg. 70 (2000), 168–173.
121. [121] Paci, E., Duffy, S.W., Giorgi, D., Zappa, M., Crocetti, E., Vezzosi, V., et al. Are breast cancer screening programmes increasing rates of mastectomy? Observational study. BMJ, 325, 2002, 418.
122. [122] Coburn, N.G., Cady, B., Fulton, J.P., Law, C., Chung, M.A., Improving size, lymph node metastatic rate, breast conservation, and mortality of invasive breast cancer in Rhode Island women, a well-screened population. Breast Cancer Res. Treat. 135 (2012), 831–837.
123. [123] Stang, A., Kaab-Sanyal, V., Hense, H.W., Becker, N., Kuss, O., Effect of mammography screening on surgical treatment for breast cancer: a nationwide analysis of hospitalization rates in Germany 2005–2009. Eur. J. Epidemiol. 28 (2013), 689–696.
124. [124] Ernst, M.F., Voogd, A.C., Coebergh, J.W., Repelaer van Driel, O.J., Roukema, J.A., The introduction of mammographical screening has had little effect on the trend in breast-conserving surgery: a population-based study in Southeast Netherlands. Eur. J. Cancer 37 (2001), 2435–2440.
125. [125] Ernst, M.F., Voogd, A.C., Coebergh, J.W.W., Roukema, J.A., An improved prognosis and a more favourable stage of the tumour in patients with invasive breast carcinoma following the introduction of the breast cancer screening programme in Tilburg: betere prognose en gunstiger tumorstadium bij patienten met invasief mammacarcinoom na de introductie van het bevolkingsonderzoek op borstkanker in Tilburg. Ned. Tijdschr. Geneeskd. 148 (2004), 378–382.
126. [126] Suhrke, P., Maehlen, J., Schlichting, E., Jorgensen, K.J., Gotzsche, P.C., Zahl, P.H., Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. BMJ, 343, 2011, d4692.
127. [127] Freedman, G.M., Anderson, P.R., Goldstein, L.J., Hanlon, A.L., Cianfrocca, M.E., Millenson, M.M., et al. Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older. Cancer 98 (2003), 918–925.
128. [128] Coldman, A.J., Phillips, N., Speers, C., A retrospective study of the effect of participation in screening mammography on the use of chemotherapy and breast conserving surgery. Int. J. Cancer 120 (2007), 2185–2190.
129. [129] Leung, A.W., Mak, J., Cheung, P.S., Epstein, R.J., Clinicopathological correlates in a cohort of Hong Kong breast cancer patients presenting with screen-detected or symptomatic disease. Hong Kong Med. J. 13 (2007), 194–198.
130. [130] Meijnen, P., Peterse, J.L., Oldenburg, H.S., Woerdeman, L.A., Rutgers, E.J., Changing patterns in diagnosis and treatment of ductal carcinoma in situ of the breast. Eur. J. Surg. Oncol. 31 (2005), 833–839.
131. [131] Palka, I., Kelemen, G., Ormandi, K., Lazar, G., Nyari, T., Thurzo, L., et al. Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol. Oncol. Res. 14 (2008), 161–167.
132. [132] Yau, T.K., Soong, I.S., Sze, H., Choi, C.W., Yeung, M.W., Ng, W.T., et al. Trends and patterns of breast conservation treatment in Hong Kong: 1994–2007. Int. J. Radiat. Oncol., Biol., Phys. 74 (2009), 98–103.
133. [133] Yen, A.M., Duffy, S.W., Chen, T.H., Chen, L.S., Chiu, S.Y., Fann, J.C., et al. Long-term incidence of breast cancer by trial arm in one county of the Swedish Two-County Trial of mammographic screening. Cancer 118 (2012), 5728–5732.
134. [134] Foca, F., Mancini, S., Bucchi, L., Puliti, D., Zappa, M., Naldoni, C., et al. Decreasing incidence of late-stage breast cancer after the introduction of organized mammography screening in Italy. Cancer 119 (2013), 2022–2028.
135. [135] Elting, L.S., Cooksley, C.D., Bekele, B.N., Giordano, S.H., Shih, Y.C., Lovell, K.K., et al. Mammography capacity impact on screening rates and breast cancer stage at diagnosis. Am. J. Prev. Med. 37 (2009), 102–108.
136. [136] Autier, P., Boniol, M., The incidence of advanced breast cancer in the West Midlands, United Kingdom. Eur. J. Cancer Prev. 21 (2012), 217–221.
137. [137] Bleyer, A., Welch, H.G., Effect of three decades of screening mammography on breast-cancer incidence. N. Engl. J. Med. 367 (2012), 1998–2005.
138. [138] Nederend, J., Duijm, L.E., Voogd, A.C., Groenewoud, J.H., Jansen, F.H., Louwman, M.W., Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study. Breast Cancer Res., 14, 2012, R10.
139. [139] Strategies IWGotEoCP, Cervix Cancer Screening. IARC Handbooks of Cancer Prevention No. 10. 2005, IARC, Lyon.
140. [140] Sankaranarayanan, R., Nene, B.M., Shastri, S.S., Jayant, K., Muwonge, R., Budukh, A.M., et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360 (2009), 1385–1394.
141. [141] Ronco, G., Dillner, J., Elfstrom, K.M., Tunesi, S., Snijders, P.J., Arbyn, M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383 (2014), 524–532.
142. [142] Ronco, G., Segnan, N., Giorgi-Rossi, P., Zappa, M., Casadei, G.P., Carozzi, F., et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J. NatL. Cancer Inst. 98 (2006), 765–774.
143. [143] Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Dalla Palma, P., Del Mistro, A., et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl. Cancer Inst. 100 (2008), 492–501.
144. [144] De Vuyst, H., Clifford, G., Li, N., Franceschi, S., HPV infection in Europe. Eur. J. Cancer 45 (2009), 2632–2639.
145. [145] Woodman, C.B., Collins, S., Winter, H., Bailey, A., Ellis, J., Prior, P., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357 (2001), 1831–1836.
146. [146] Vesco, K.K., Whitlock, E.P., Eder, M., Lin, J., Burda, B.U., Senger, C.A., Holmes, R.S., Fu, R., Zuber, S., Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 86. AHRQ Publication No. 11-05156-EF-1. 2011, Agency for Healthcare Research and Quality, Rockville, MD.
147. [147] Arbyn, M., Ronco, G., Meijer, C.J., Naucler, P., Trials comparing cytology with human papillomavirus screening. Lancet Oncol. 10 (2009), 935–936.
148. [148] Cuzick, J., Arbyn, M., Sankaranarayanan, R., Tsu, V., Ronco, G., Mayrand, M.H., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26:Suppl. 10 (2008), K29–41.
149. [149] Cuzick, J., Mayrand, M.H., Ronco, G., Snijders, P., Wardle, J., Chapter 10: new dimensions in cervical cancer screening. Vaccine 24:Suppl. 3:S3 (2006), 90–97.
150. [150] Kim, J.J., Wright, T.C., Goldie, S.J., Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J. Natl. Cancer Inst. 97 (2005), 888–895.
151. [151] Ronco, G., Biggeri, A., Confortini, M., Naldoni, C., Segnan, N., Sideri, M., et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors. Epidemiol. Prev. 36 (2012), e1–72.
152. [152] Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Dalla Palma, P., Del Mistro, A., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11 (2010), 249–257.
153. [153] Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. Br. Med. J. (Clin. Res. Ed.) 1986, 293 (September (6548)), 659–664.
154. [154] van den Akker-van Marle, M.E., van Ballegooijen, M., Habbema, J.D., Low risk of cervical cancer during a long period after negative screening in the Netherlands. Br. J. Cancer 88 (2003), 1054–1057.
155. [155] Sasieni, P., Adams, J., Cuzick, J., Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br. J. Cancer 89 (2003), 88–93.
156. [156] Rijkaart, D.C., Berkhof, J., Rozendaal, L., van Kemenade, F.J., Bulkmans, N.W., Heideman, D.A., et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 13 (2012), 78–88.
157. [157] Kitchener, H.C., Almonte, M., Thomson, C., Wheeler, P., Sargent, A., Stoykova, B., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 10 (2009), 672–682.
158. [158] Naucler, P., Ryd, W., Tornberg, S., Strand, A., Wadell, G., Elfgren, K., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357 (2007), 1589–1597.
159. [159] Naucler, P., Ryd, W., Tornberg, S., Strand, A., Wadell, G., Elfgren, K., et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J. Natl. Cancer Inst. 101 (2009), 88–99.
160. [160] Arbyn, M., Ronco, G., Anttila, A., Meijer, C.J., Poljak, M., Ogilvie, G., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30:Suppl. 5 (2012), F88–99.
161. [161] Bulk, S., Bulkmans, N.W., Berkhof, J., Rozendaal, L., Boeke, A.J., Verheijen, R.H., et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int. J. Cancer 121 (2007), 361–367.
162. [162] Schneider, A., Hoyer, H., Lotz, B., Leistritza, S., Kuhne-Heid, R., Nindl, I., et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int. J. Cancer 89 (2000), 529–534.
163. [163] Patanwala, I.Y., Bauer, H.M., Miyamoto, J., Park, I.U., Huchko, M.J., Smith-McCune, K.K., A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening. Am. J. Obstet. Gynecol. 208 (2013), 343–353.
164. [164] Leinonen, M., Nieminen, P., Kotaniemi-Talonen, L., Malila, N., Tarkkanen, J., Laurila, P., et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl. Cancer Inst. 101 (2009), 1612–1623.
165. [165] Group, T., Cytological surveillance compared with immediate referral for colposcopy in management of women with low grade cervical abnormalities: multicentre randomised controlled trial. BMJ, 339, 2009, b2546.
166. [166] Group, T., Sharp, L., Cotton, S., Cochran, C., Gray, N., Little, J., et al. After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG 116 (2009), 1506–1514.
167. [167] Kyrgiou, M., Koliopoulos, G., Martin-Hirsch, P., Arbyn, M., Prendiville, W., Paraskevaidis, E., Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367 (2006), 489–498.
168. [168] Arbyn, M., Kyrgiou, M., Simoens, C., Raifu, A.O., Koliopoulos, G., Martin-Hirsch, P., et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ, 337, 2008, a1284.
169. [169] Werner, C.L., Lo, J.Y., Heffernan, T., Griffith, W.F., McIntire, D.D., Leveno, K.J., Loop electrosurgical excision procedure and risk of preterm birth. Obstet. Gynecol. 115 (2010), 605–608.
170. [170] Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Belanger, A., Brousseau, G., et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 59 (2004), 311–318.
171. [171] Kjellman, A., Akre, O., Norming, U., Tornblom, M., Gustafsson, O., 15-year followup of a population based prostate cancer screening study. J. Urol. 181 (2009), 1615–1621 discussion 21.
172. [172] Sandblom, G., Varenhorst, E., Rosell, J., Lofman, O., Carlsson, P., Randomised prostate cancer screening trial: 20 year follow-up. BMJ, 342, 2011, d1539.
173. [173] Andriole, G.L., Crawford, E.D., Grubb 3rd, R.L., Buys, S.S., Chia, D., Church, T.R., et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J. Natl. Cancer Inst. 104 (2012), 125–132.
174. [174] Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., Nelen, V., et al. Prostate-cancer mortality at 11 years of follow-up. N. Engl. J. Med. 366 (2012), 981–990.
175. [175] Ilic, D., Neuberger, M.M., Djulbegovic, M., Dahm, P., Screening for prostate cancer. Cochrane Database Syst. Rev., 1, 2013, CD004720.